研究单位：[1]AnchorDx Medical Co.,Ltd.[2]Department of Respiratory Medicine,The First People's Hospital of Yunnan Province Kunming,China[3]Department of Gerontal Respiratory Medicine,The Frist Hospital of Lanzhou University Lanzhou,China[4]Department of Respiration,The First Affiliated Hospital of Nanchang University Nanchang,China[5]Department of Pulmonary & Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine Shanghai,China[6]Department of Pulmonary Medicine,Shanghai Chest Hospital,Shanghai Jiaotong University Shanghai,China[7]Department of Pulmonary Medicine,Zhongshan Hospital,Fudan University Shanghai,China[8]Department of Respiratory Medicine,Shanghai Pulmonary Hospital,Tongji University School of Medicine Shanghai,China[9]Department of Respiratory Medicine,Shantou Central Hospital Shantou,China
AnchorDx is using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS) to develop a blood-based assay for differentiating benign and malignant pulmonary nodules early. The purpose of this study is to evaluate the diagnostic performance of this assay in patients with pulmonary nodules.
